Evidence map›Paper›PMID 34174935›Full record

ArticleBreast cancer research : BCR2021

Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya.

Shahin Sayed, Shaoqi Fan, Zahir Moloo, Ronald Wasike, Peter Bird, Mansoor Saleh, Asim Jamal Shaikh, Jonine D Figueroa, Richard Naidoo, Francis W Makokha and 9 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Relationship between early age at menarche, older age at menopause and subtypes of breast cancer: a scoping review.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024
    Article
  11. Oncogenic roles of GPR176 in breast cancer: a potential marker of aggressiveness and a potential target of gene therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Shahin SayedDepartment of Pathology, Aga Khan University, Nairobi, Kenya. shaheen.sayed@aku.edu.ORCID 0000-0002-3472-511X
Shaoqi FanNational Cancer Institute of the National Institutes of Health (NCI/NIH) Bethesda, Maryland, Rockville, USA.
Zahir MolooDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Ronald WasikeDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Peter BirdAIC Kijabe Hospital, Kijabe, Kenya.
Mansoor SalehDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Asim Jamal ShaikhDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Jonine D FigueroaThe University of Edinburgh, Edinburgh, UK.
Richard NaidooUniversity of Cape Town, Cape Town, South Africa.
Francis W MakokhaMount Kenya University, Thika, Kenya.
Kevin GardnerColumbia University Medical Centre, New York, USA.
Raymond OigaraSt. Mary's Mission Hospital, Nairobi, Kenya.
Faith Wambui NjorogeNyeri Provincial General Hospital, Nyeri, Kenya.
Pumza MaganganeUniversity of the Witwatersrand, Johannesburg, South Africa.
Miriam MutebiDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Rajendra ChauhanDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Sitna MwanziDepartment of Pathology, Aga Khan University, Nairobi, Kenya.
Dhirendra Govender *University of Cape Town, Cape Town, South Africa.
Xiaohong R Yang *National Cancer Institute of the National Institutes of Health (NCI/NIH) Bethesda, Maryland, Rockville, USA.

Funding

Aga Khan University Deans FundDivision of Cancer Epidemiology and Genetics, National Cancer Institute intramural research programGlaxoSmithKline 2011-GSK-ERI/GlaxoSmithKline/International.Medical Research Council MR/S015027/1
6 · The paper itself

Abstract

backgroundFew studies have investigated risk factor heterogeneity by molecular subtypes in indigenous African populations where prevalence of traditional breast cancer (BC) risk factors, genetic background, and environmental exposures show marked differences compared to European ancestry populations.

methodsWe conducted a case-only analysis of 838 pathologically confirmed BC cases recruited from 5 groups of public, faith-based, and private institutions across Kenya between March 2012 to May 2015. Centralized pathology review and immunohistochemistry (IHC) for key markers (ER, PR, HER2, EGFR, CK5-6, and Ki67) was performed to define subtypes. Risk factor data was collected at time of diagnosis through a questionnaire. Multivariable polytomous logistic regression models were used to determine associations between BC risk factors and tumor molecular subtypes, adjusted for clinical characteristics and risk factors.

resultsThe median age at menarche and first pregnancy were 14 and 21 years, median number of children was 3, and breastfeeding duration was 62 months per child. Distribution of molecular subtypes for luminal A, luminal B, HER2-enriched, and triple negative (TN) breast cancers was 34.8%, 35.8%, 10.7%, and 18.6%, respectively. After adjusting for covariates, compared to patients with ER-positive tumors, ER-negative patients were more likely to have higher parity (OR = 2.03, 95% CI = (1.11, 3.72), p = 0.021, comparing ≥ 5 to ≤ 2 children). Compared to patients with luminal A tumors, luminal B patients were more likely to have lower parity (OR = 0.45, 95% CI = 0.23, 0.87, p = 0.018, comparing ≥ 5 to ≤ 2 children); HER2-enriched patients were less likely to be obese (OR = 0.36, 95% CI = 0.16, 0.81, p = 0.013) or older age at menopause (OR = 0.38, 95% CI = 0.15, 0.997, p = 0.049). Body mass index (BMI), either overall or by menopausal status, did not vary significantly by ER status. Overall, cumulative or average breastfeeding duration did not vary significantly across subtypes.

conclusionsIn Kenya, we found associations between parity-related risk factors and ER status consistent with observations in European ancestry populations, but differing associations with BMI and breastfeeding. Inclusion of diverse populations in cancer etiology studies is needed to develop population and subtype-specific risk prediction/prevention strategies.

Indexed as

AdultBiomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHospitalsHumansKenyaMiddle AgedReceptors, EstrogenReceptors, ProgesteroneReproductive Physiological PhenomenaRisk FactorsSociodemographic FactorsBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerKenyaMolecular subtypesRisk factorsSub-Saharan Africa

Identifiers

PMID34174935
PMCPMC8235821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.